In this randomized , double-blind , non-inferiority , active-controlled study , adult subjects with CKD-ND , Hb levels < 10g/dL , and not treated with an erythropoiesis-stimulating agent were randomized 1:1 to receive DA every 2 weeks ( Q2W ) or QM for 33 weeks with initial doses of 0.75 g/kg Q2W or 1.5 g/kg QM .